Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.
The company’s goal is to be a global leader in iron deficiency, nephrology and cardio-renal therapies and strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
Vifor Pharma Group has production sites in Switzerland and Portugal as well as a dynamic network of affiliates and partners offering broad market coverage all over the world.
The company has an ever-growing global presence while at the same time remaining firmly rooted in its home market, Switzerland and is listed on the Swiss Stock Exchange.
Vifor Pharma Group consists of Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, its joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
G.L. Pharma was formed out of a merger of the two pharmaceutical companies Gerot and Lannacher and is looking back at a history of more than 60 years.
They serve their clients with products from our state-of-the-art manufacturing as well as distribution facility based in the heart of Austria.
They develop, produce and allocate unique brand name products as well as generics for the well-being of people in Austria and abroad. As a supplier to Austria’s healthcare sector, they partner with general practitioners, pharmacists, their patients and pharmaceutical wholesalers. As an international player, they market their products through their licensees and branch offices to more than 50 countries. Their core competence concentrates on three different business areas:
– Cardiovascular system
– Central nervous system
– Urology, oncology, opioid substitution therapy
With its unique expertise in the field of immunology, OM Pharma develops and manufactures infectious diseases/OTX products for respiratory tract infections, lower urinary tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, chronic venous insufficiency, diabetic retinopathy, haemorrhoids, menometrorrhagia (heavy menstrual bleeding).
they are excellent complements to ViforPharma Group’s other therapeutic areas.
The company is in trade with medicinal goods and drugs: Licensing, trading and distribution of pharmaceutical products, medicinal products and other products within the healthcare sector, all domestic and foreign related activities and the provision of related advisory services and training to authorities, businesses and individuals.
